Review





Similar Products

oe vhl  (MedChemExpress)
96
MedChemExpress oe vhl
Oe Vhl, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oe vhl/product/MedChemExpress
Average 96 stars, based on 1 article reviews
oe vhl - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
copy number variation vhl hs02125257 cn  (Thermo Fisher)
94
Thermo Fisher copy number variation vhl hs02125257 cn
Clinical characteristics of the study population and general description of genetic findings. (A) Sex distribution of the probands (n = 92). (B) Categories of clinical presentation of the study probands (n = 92). The categories were determined according to the clinical features observed at diagnosis and during follow-up. (C) Family history in probands (n = 92). Patients with no relevant family history were classified as sporadic and the rest were grouped into 10 categories, according to the phenotypes described in the family members. (D) All variants (n = 303) identified in the study, according to their predicted effect. (E) ACMG/AMP categories for all variants identified in the study (n = 303). (F) Comparison of the age at disease onset and diagnosis between individuals with a detected pathogenic or likely pathogenic variant (P/LP) and the rest of probands (Rest). The horizontal bar represents median, and the error bars depict interquartile range. CS, Cushing's syndrome; del, deletion; dup, duplication; FIPA, familial isolated pituitary adenoma; FMTC, familial medullary thyroid carcinoma; FPPGLs, familial pheochromocytomas/paragangliomas; gig/EO acro, gigantism and early onset acromegaly; ins, insertion; ins/del, insertion/deletion; LB, likely benign; LFL, Li–Fraumeni-like; LP, likely pathogenic; MEN-like, syndrome similar to multiple endocrine neoplasia; MEN1, multiple endocrine neoplasia type 1; MEN2A, multiple endocrine neoplasia type 2A; MTC, medullary thyroid carcinoma; M GI-NENs, multiple gastrointestinal neuroendocrine neoplasms; M panNENs, multiple pancreatic neuroendocrine neoplasms; NF1, neurofibromatosis type 1; non-GH EO PitNETs, early onset PitNETs not causing GH excess; panNEN, pancreatic neuroendocrine neoplasm; PitNET, pituitary neuroendocrine tumor; PPGL, pheochromocytoma/paraganglioma; <t>VHL,</t> Von Hippel Lindau syndrome; VUS, variants of uncertain significance.
Copy Number Variation Vhl Hs02125257 Cn, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/copy number variation vhl hs02125257 cn/product/Thermo Fisher
Average 94 stars, based on 1 article reviews
copy number variation vhl hs02125257 cn - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
ahpc me hydrochloride vhl ligand  (MedChemExpress)
94
MedChemExpress ahpc me hydrochloride vhl ligand
Clinical characteristics of the study population and general description of genetic findings. (A) Sex distribution of the probands (n = 92). (B) Categories of clinical presentation of the study probands (n = 92). The categories were determined according to the clinical features observed at diagnosis and during follow-up. (C) Family history in probands (n = 92). Patients with no relevant family history were classified as sporadic and the rest were grouped into 10 categories, according to the phenotypes described in the family members. (D) All variants (n = 303) identified in the study, according to their predicted effect. (E) ACMG/AMP categories for all variants identified in the study (n = 303). (F) Comparison of the age at disease onset and diagnosis between individuals with a detected pathogenic or likely pathogenic variant (P/LP) and the rest of probands (Rest). The horizontal bar represents median, and the error bars depict interquartile range. CS, Cushing's syndrome; del, deletion; dup, duplication; FIPA, familial isolated pituitary adenoma; FMTC, familial medullary thyroid carcinoma; FPPGLs, familial pheochromocytomas/paragangliomas; gig/EO acro, gigantism and early onset acromegaly; ins, insertion; ins/del, insertion/deletion; LB, likely benign; LFL, Li–Fraumeni-like; LP, likely pathogenic; MEN-like, syndrome similar to multiple endocrine neoplasia; MEN1, multiple endocrine neoplasia type 1; MEN2A, multiple endocrine neoplasia type 2A; MTC, medullary thyroid carcinoma; M GI-NENs, multiple gastrointestinal neuroendocrine neoplasms; M panNENs, multiple pancreatic neuroendocrine neoplasms; NF1, neurofibromatosis type 1; non-GH EO PitNETs, early onset PitNETs not causing GH excess; panNEN, pancreatic neuroendocrine neoplasm; PitNET, pituitary neuroendocrine tumor; PPGL, pheochromocytoma/paraganglioma; <t>VHL,</t> Von Hippel Lindau syndrome; VUS, variants of uncertain significance.
Ahpc Me Hydrochloride Vhl Ligand, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ahpc me hydrochloride vhl ligand/product/MedChemExpress
Average 94 stars, based on 1 article reviews
ahpc me hydrochloride vhl ligand - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
vhl  (Proteintech)
93
Proteintech vhl
Clinical characteristics of the study population and general description of genetic findings. (A) Sex distribution of the probands (n = 92). (B) Categories of clinical presentation of the study probands (n = 92). The categories were determined according to the clinical features observed at diagnosis and during follow-up. (C) Family history in probands (n = 92). Patients with no relevant family history were classified as sporadic and the rest were grouped into 10 categories, according to the phenotypes described in the family members. (D) All variants (n = 303) identified in the study, according to their predicted effect. (E) ACMG/AMP categories for all variants identified in the study (n = 303). (F) Comparison of the age at disease onset and diagnosis between individuals with a detected pathogenic or likely pathogenic variant (P/LP) and the rest of probands (Rest). The horizontal bar represents median, and the error bars depict interquartile range. CS, Cushing's syndrome; del, deletion; dup, duplication; FIPA, familial isolated pituitary adenoma; FMTC, familial medullary thyroid carcinoma; FPPGLs, familial pheochromocytomas/paragangliomas; gig/EO acro, gigantism and early onset acromegaly; ins, insertion; ins/del, insertion/deletion; LB, likely benign; LFL, Li–Fraumeni-like; LP, likely pathogenic; MEN-like, syndrome similar to multiple endocrine neoplasia; MEN1, multiple endocrine neoplasia type 1; MEN2A, multiple endocrine neoplasia type 2A; MTC, medullary thyroid carcinoma; M GI-NENs, multiple gastrointestinal neuroendocrine neoplasms; M panNENs, multiple pancreatic neuroendocrine neoplasms; NF1, neurofibromatosis type 1; non-GH EO PitNETs, early onset PitNETs not causing GH excess; panNEN, pancreatic neuroendocrine neoplasm; PitNET, pituitary neuroendocrine tumor; PPGL, pheochromocytoma/paraganglioma; <t>VHL,</t> Von Hippel Lindau syndrome; VUS, variants of uncertain significance.
Vhl, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vhl/product/Proteintech
Average 93 stars, based on 1 article reviews
vhl - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
crbn 6 5 5 vhl  (MedChemExpress)
94
MedChemExpress crbn 6 5 5 vhl
Clinical characteristics of the study population and general description of genetic findings. (A) Sex distribution of the probands (n = 92). (B) Categories of clinical presentation of the study probands (n = 92). The categories were determined according to the clinical features observed at diagnosis and during follow-up. (C) Family history in probands (n = 92). Patients with no relevant family history were classified as sporadic and the rest were grouped into 10 categories, according to the phenotypes described in the family members. (D) All variants (n = 303) identified in the study, according to their predicted effect. (E) ACMG/AMP categories for all variants identified in the study (n = 303). (F) Comparison of the age at disease onset and diagnosis between individuals with a detected pathogenic or likely pathogenic variant (P/LP) and the rest of probands (Rest). The horizontal bar represents median, and the error bars depict interquartile range. CS, Cushing's syndrome; del, deletion; dup, duplication; FIPA, familial isolated pituitary adenoma; FMTC, familial medullary thyroid carcinoma; FPPGLs, familial pheochromocytomas/paragangliomas; gig/EO acro, gigantism and early onset acromegaly; ins, insertion; ins/del, insertion/deletion; LB, likely benign; LFL, Li–Fraumeni-like; LP, likely pathogenic; MEN-like, syndrome similar to multiple endocrine neoplasia; MEN1, multiple endocrine neoplasia type 1; MEN2A, multiple endocrine neoplasia type 2A; MTC, medullary thyroid carcinoma; M GI-NENs, multiple gastrointestinal neuroendocrine neoplasms; M panNENs, multiple pancreatic neuroendocrine neoplasms; NF1, neurofibromatosis type 1; non-GH EO PitNETs, early onset PitNETs not causing GH excess; panNEN, pancreatic neuroendocrine neoplasm; PitNET, pituitary neuroendocrine tumor; PPGL, pheochromocytoma/paraganglioma; <t>VHL,</t> Von Hippel Lindau syndrome; VUS, variants of uncertain significance.
Crbn 6 5 5 Vhl, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/crbn 6 5 5 vhl/product/MedChemExpress
Average 94 stars, based on 1 article reviews
crbn 6 5 5 vhl - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
anti vhl  (Proteintech)
93
Proteintech anti vhl
Clinical characteristics of the study population and general description of genetic findings. (A) Sex distribution of the probands (n = 92). (B) Categories of clinical presentation of the study probands (n = 92). The categories were determined according to the clinical features observed at diagnosis and during follow-up. (C) Family history in probands (n = 92). Patients with no relevant family history were classified as sporadic and the rest were grouped into 10 categories, according to the phenotypes described in the family members. (D) All variants (n = 303) identified in the study, according to their predicted effect. (E) ACMG/AMP categories for all variants identified in the study (n = 303). (F) Comparison of the age at disease onset and diagnosis between individuals with a detected pathogenic or likely pathogenic variant (P/LP) and the rest of probands (Rest). The horizontal bar represents median, and the error bars depict interquartile range. CS, Cushing's syndrome; del, deletion; dup, duplication; FIPA, familial isolated pituitary adenoma; FMTC, familial medullary thyroid carcinoma; FPPGLs, familial pheochromocytomas/paragangliomas; gig/EO acro, gigantism and early onset acromegaly; ins, insertion; ins/del, insertion/deletion; LB, likely benign; LFL, Li–Fraumeni-like; LP, likely pathogenic; MEN-like, syndrome similar to multiple endocrine neoplasia; MEN1, multiple endocrine neoplasia type 1; MEN2A, multiple endocrine neoplasia type 2A; MTC, medullary thyroid carcinoma; M GI-NENs, multiple gastrointestinal neuroendocrine neoplasms; M panNENs, multiple pancreatic neuroendocrine neoplasms; NF1, neurofibromatosis type 1; non-GH EO PitNETs, early onset PitNETs not causing GH excess; panNEN, pancreatic neuroendocrine neoplasm; PitNET, pituitary neuroendocrine tumor; PPGL, pheochromocytoma/paraganglioma; <t>VHL,</t> Von Hippel Lindau syndrome; VUS, variants of uncertain significance.
Anti Vhl, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vhl/product/Proteintech
Average 93 stars, based on 1 article reviews
anti vhl - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


Clinical characteristics of the study population and general description of genetic findings. (A) Sex distribution of the probands (n = 92). (B) Categories of clinical presentation of the study probands (n = 92). The categories were determined according to the clinical features observed at diagnosis and during follow-up. (C) Family history in probands (n = 92). Patients with no relevant family history were classified as sporadic and the rest were grouped into 10 categories, according to the phenotypes described in the family members. (D) All variants (n = 303) identified in the study, according to their predicted effect. (E) ACMG/AMP categories for all variants identified in the study (n = 303). (F) Comparison of the age at disease onset and diagnosis between individuals with a detected pathogenic or likely pathogenic variant (P/LP) and the rest of probands (Rest). The horizontal bar represents median, and the error bars depict interquartile range. CS, Cushing's syndrome; del, deletion; dup, duplication; FIPA, familial isolated pituitary adenoma; FMTC, familial medullary thyroid carcinoma; FPPGLs, familial pheochromocytomas/paragangliomas; gig/EO acro, gigantism and early onset acromegaly; ins, insertion; ins/del, insertion/deletion; LB, likely benign; LFL, Li–Fraumeni-like; LP, likely pathogenic; MEN-like, syndrome similar to multiple endocrine neoplasia; MEN1, multiple endocrine neoplasia type 1; MEN2A, multiple endocrine neoplasia type 2A; MTC, medullary thyroid carcinoma; M GI-NENs, multiple gastrointestinal neuroendocrine neoplasms; M panNENs, multiple pancreatic neuroendocrine neoplasms; NF1, neurofibromatosis type 1; non-GH EO PitNETs, early onset PitNETs not causing GH excess; panNEN, pancreatic neuroendocrine neoplasm; PitNET, pituitary neuroendocrine tumor; PPGL, pheochromocytoma/paraganglioma; VHL, Von Hippel Lindau syndrome; VUS, variants of uncertain significance.

Journal: The Journal of Clinical Endocrinology and Metabolism

Article Title: Overlapping Presentations and Diverse Genetic Defects Characterize Neuroendocrine Neoplasms in a Mexican Cohort

doi: 10.1210/clinem/dgaf075

Figure Lengend Snippet: Clinical characteristics of the study population and general description of genetic findings. (A) Sex distribution of the probands (n = 92). (B) Categories of clinical presentation of the study probands (n = 92). The categories were determined according to the clinical features observed at diagnosis and during follow-up. (C) Family history in probands (n = 92). Patients with no relevant family history were classified as sporadic and the rest were grouped into 10 categories, according to the phenotypes described in the family members. (D) All variants (n = 303) identified in the study, according to their predicted effect. (E) ACMG/AMP categories for all variants identified in the study (n = 303). (F) Comparison of the age at disease onset and diagnosis between individuals with a detected pathogenic or likely pathogenic variant (P/LP) and the rest of probands (Rest). The horizontal bar represents median, and the error bars depict interquartile range. CS, Cushing's syndrome; del, deletion; dup, duplication; FIPA, familial isolated pituitary adenoma; FMTC, familial medullary thyroid carcinoma; FPPGLs, familial pheochromocytomas/paragangliomas; gig/EO acro, gigantism and early onset acromegaly; ins, insertion; ins/del, insertion/deletion; LB, likely benign; LFL, Li–Fraumeni-like; LP, likely pathogenic; MEN-like, syndrome similar to multiple endocrine neoplasia; MEN1, multiple endocrine neoplasia type 1; MEN2A, multiple endocrine neoplasia type 2A; MTC, medullary thyroid carcinoma; M GI-NENs, multiple gastrointestinal neuroendocrine neoplasms; M panNENs, multiple pancreatic neuroendocrine neoplasms; NF1, neurofibromatosis type 1; non-GH EO PitNETs, early onset PitNETs not causing GH excess; panNEN, pancreatic neuroendocrine neoplasm; PitNET, pituitary neuroendocrine tumor; PPGL, pheochromocytoma/paraganglioma; VHL, Von Hippel Lindau syndrome; VUS, variants of uncertain significance.

Article Snippet: A commercial predesigned assay (Applied Biosystems TaqMan 6-carboxyfluorescein-labeled Hs02125257_cn) was used for ddPCR for VHL exon 3.

Techniques: Biomarker Discovery, Comparison, Variant Assay, Isolation